Alemtuzumab, a humanized anti - CD 52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿仑单抗, 一种人源性 抗 -CD52抗体, 在免疫耐受诱导方案中效果显著, 需要最少的免疫抑制维持药物.
Methods also provided for generating tolerogenic dendritic cells and regulatory T cells.
本发明也提供了产生致耐受性树突细胞和调节性T细胞的方法.